<DOC>
	<DOCNO>NCT00334542</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . The use simvastatin may keep cancer come back woman high risk new breast cancer undergo surgery ductal carcinoma situ stage I , stage II , stage III breast cancer . PURPOSE : This phase II trial study well simvastatin work prevent new breast cancer woman high risk new breast cancer undergo surgery ductal carcinoma situ stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Simvastatin Preventing New Breast Cancer Women High Risk New Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Describe change baseline panel biomarkers ( high-sensitivity C-reactive protein [ hsCRP ] , lipid profile , circulate estrogen , contralateral breast density ) woman high risk develop new breast cancer undergone surgical resection history ductal carcinoma situ stage I-III invasive breast cancer treat simvastatin . Secondary - Correlate change panel biomarkers wild-type versus polymorphic 3-hydroxyl-3-methylglutaryl-Coenzyme A ( HMG-CoA ) reductase woman treat simvastatin . Tertiary - Evaluate methylation status across panel gene know frequently specifically hypermethylated ductal carcinoma situ ( DCIS ) invasive breast cancer ( estrogen receptor [ ER ] -α ER-β , cyclin D2 , RAR-β , Twist , RASSF1A , HIN-1 ) correlate change cumulative methylation change hsCRP , lipid profile , contralateral breast density , estrogen concentration , pharmacogenetics . - Measure change phosphoinositide 3'-kinase ( PI3K ) /protein kinase B ( Akt ) signal pathway ( Akt p-Akt ) treatment simvastatin . OUTLINE : This multicenter study . Patients stratify accord menopausal status ( pre- v post-menopausal ) . Patients receive oral simvastatin daily 24-28 week absence disease progression unacceptable toxicity . Patients undergo blood collection baseline end study treatment pharmacogenetic biomarker correlative study . Patients undergo mammography measurement breast density contralateral breast baseline end study treatment . Quality life assess baseline end study treatment . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : History histologically confirm breast cancer , meet 1 follow stag criterion : Ductal carcinoma situ Stage IIII invasive breast cancer At least 3 month since completion intend local systemic therapy , include mastectomy lumpectomy without radiotherapy , adjuvant chemotherapy , and/or endocrine therapy May decline recommend treatment provide treatment intended/agreed upon patient treat physician complete ≥ 3 month ago At least 1 healthy intact breast No prior radiotherapy mastectomy Prior biopsy allow Any hormonereceptor status PATIENT CHARACTERISTICS : Female Pre postmenopausal ECOG performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception No active liver disease AST ALT ≤ 3 time upper limit normal Creatinine clearance ≥ 30 mL/min No prior hypersensitivity 3hydroxyl3methylglutarylCoenzyme A ( HMGCoA ) reductase inhibitor components No concurrent infectious , inflammatory , autoimmune disease ( discretion principal investigator ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No daily alcohol use &gt; 3 standard drink per day Standard drink define 10 gram alcohol , equivalent 285 mL beer , 530 mL light beer , 100 mL wine , 30 mL liquor No selective estrogen receptor modulator aromatase inhibitor within past 3 month No hormone replacement therapy ( HRT ) within past 3 month No prior estrogen and/or progesterone HRT ≥ 5 year duration Vaginal estrogen preparation allow No concurrent HRT No cholesterollowering drug , include statin , within past 3 month No concurrent itraconazole , ketoconazole , nefazodone , cyclosporine , HIV protease inhibitor , clarithromycin , erythromycin , mibefradil , carbamazepine , bosentan , chaparral , amiodarone , verapamil No concurrent daily grapefruit juice consumption &gt; 8 ounce per day No concurrent agent therapy intend treat prevent situ invasive breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>